Brand-name semaglutide (sold as Ozempic and Wegovy) is an FDA-approved medication manufactured by Novo Nordisk. Compounded semaglutide is a version mixed by compounding pharmacies that has not gone through FDA approval. While both are intended to deliver the same active drug, they differ in chemical form, quality testing, delivery method, added ingredients, and price.
The Active Ingredient Is Not Always the Same
This is the most important distinction, and it surprises many people. FDA-approved Ozempic and Wegovy use semaglutide in its “base” form, the exact molecular structure that was tested in clinical trials. Many compounding pharmacies instead use semaglutide sodium or semaglutide acetate. These are salt forms of the molecule, and the FDA considers them chemically distinct active ingredients that have never been evaluated for safety or effectiveness in a finished drug product.
Why does this matter? Changing the salt form of a peptide drug can alter how it dissolves, how stable it remains over time, and how it behaves once injected. The FDA has stated it is unaware of any scientific basis for compounding with these salt forms. In practical terms, a patient receiving semaglutide acetate is getting something that has never been through the rigorous testing process that the base form underwent.
Quality Control and Purity
Brand-name semaglutide is produced under strict FDA manufacturing standards, with each batch tested for consistency, potency, and contamination. Compounding pharmacies operate under different, less stringent oversight. Researchers who analyzed samples of compounded semaglutide found dangerous impurities including trace metals and residual solvents. Some samples contained formaldehyde-related byproducts. Others contained BPC-157, a substance not approved for human use in the United States.
Compounding pharmacies also frequently add extra ingredients to their semaglutide formulations, including vitamin B-12, vitamin B-6, L-carnitine, and NAD. The safety and effectiveness of combining semaglutide with any of these additives has not been established. These additions are marketed as beneficial, but no clinical trial has tested whether they interact with semaglutide or change its effects in the body.
Dosing Errors Are a Serious Risk
Brand-name Ozempic and Wegovy come in prefilled pens with a dial that clicks to the correct dose. Compounded semaglutide typically comes in multi-dose vials, requiring the patient to draw up the correct amount using a syringe. This difference has led to a pattern of dangerous dosing mistakes that prompted an FDA safety alert.
The FDA received reports of patients accidentally injecting 5 to 20 times the intended dose of compounded semaglutide. The errors happened for two reasons: patients unfamiliar with syringes drew up too much medication, and healthcare providers miscalculated doses when converting between milligrams, milliliters, and “units.” Adverse events from these overdoses included severe nausea and vomiting, fainting, dehydration, acute pancreatitis, and gallstones. Some patients required hospitalization.
Prefilled pens eliminate most of this risk because the dosing mechanism is built into the device. With a vial and syringe, the margin for error is significant, especially for someone who has never self-injected before.
Cost Differences
Price is the primary reason people seek out compounded semaglutide. The gap is substantial. Wegovy’s list price runs $1,349 to $1,418 per month, and Ozempic costs $950 to $1,051 monthly. Compounded semaglutide typically costs $194 to $399 per month, with some introductory offers as low as $129.
That said, manufacturer savings programs can dramatically reduce brand-name costs for eligible patients. The Wegovy Savings Card covers the first 13 fills at no cost, then drops to $25 per fill. The Ozempic Savings Card brings eligible patients down to $25 per fill as well. These programs generally require commercial insurance and exclude government insurance plans like Medicare and Medicaid. Compounded semaglutide is almost never covered by insurance, so the out-of-pocket price is fixed.
The Legal Landscape Has Changed
Compounding pharmacies were legally permitted to make semaglutide because the drug was on the FDA’s official shortage list, starting in March 2022 for Wegovy and August 2022 for Ozempic. Under federal law, compounders can produce copies of FDA-approved drugs when those drugs are in shortage.
As of February 2025, the FDA determined that the semaglutide injection shortage is resolved. This changes the legal basis for compounding. With the shortage officially over, compounding pharmacies face new restrictions on producing semaglutide products. The FDA has said it will continue monitoring supply and demand and could relist semaglutide if shortages return, but for now, the regulatory window that allowed widespread compounding has narrowed.
How to Weigh the Trade-Offs
The appeal of compounded semaglutide is straightforward: it costs a fraction of the brand-name price. For people without insurance coverage or savings card eligibility, the difference between $300 and $1,300 a month is the difference between affording treatment and not.
The risks are equally concrete. You may receive a product made with a different chemical form of the drug than what was tested in clinical trials. The purity and potency can vary between batches and between pharmacies. The vial-and-syringe delivery method introduces real dosing dangers, particularly for people new to injections. And the added ingredients common in compounded formulations are untested in combination with semaglutide.
If you’re considering compounded semaglutide, it helps to ask the pharmacy directly whether they use the base form or a salt form, what third-party testing they perform on their products, and whether they provide clear dosing instructions calibrated to the specific concentration in your vial. Not all compounding pharmacies carry the same level of risk, but none of them offer the same regulatory guarantees as an FDA-approved product.